A previous study in mice have shown that the pharmacological inhibition of PAD4 delayed tumor progression and could sensitize cancer cells to combined immunotherapy with anti-PD-1 and anti-CTLA-4 checkpoint inhibitors [75]. Here, CTLA4 is linked to cancer.